What are the main business models in neurotechnology?

Is neurotechnology basically a BCI market now?

Neurotechnology today is still commercially dominated by implanted neuromodulation and clinical brain monitoring, while high-bandwidth brain-computer interfaces remain tiny in revenue terms.

The gap between attention and actual business is enormous. Medtronic’s latest annual filing shows $2.07 billion of neuromodulation sales, up from $1.75 billion two years earlier. LivaNova generated another $318.7 million from neuromodulation in the first half of 2026 alone. NeuroPace, which is much smaller and focused on responsive brain stimulation for epilepsy, generated $22.5 million from its RNS system in its latest quarter, up 21% year over year.

Compare that with the companies most people associate with cutting-edge neurotechnology. Neuralink announced 21 participants across its clinical trials earlier this year. Paradromics has only recently completed the first long-term implant in its FDA-approved Connect-One study. Synchron raised another $200 million to push its Stentrode BCI toward commercialization.

So two very different neurotech markets are developing at the same time. One already sells thousands of clinically approved systems through hospitals and reimbursement. The other is trying to prove that much more powerful brain interfaces can become safe, repeatable medical products.

For now, most neurotechnology money is still being made by treating neurological problems rather than by turning thoughts into computer commands.

Where is neurotech actually making money today?

Neurotech companies currently make money through six main models, but only a few of them have already proved they can support large businesses.

The biggest category is reimbursed therapeutic devices such as deep-brain stimulators, spinal-cord stimulators, vagus-nerve stimulators and responsive neurostimulation systems. Hospitals perform procedures, healthcare systems or insurers ultimately pay for them, and manufacturers sell the implant and related equipment.

Clinical monitoring has a different rhythm. Companies can install equipment inside a hospital, charge for software and then sell something every time another patient is tested. Ceribell does this with disposable EEG headbands and a monthly software subscription.

Research neurotechnology works through equipment and software sold to universities, pharmaceutical companies and neuroscience laboratories. Consumer neurotechnology relies mainly on people paying directly for EEG headsets, neurofeedback devices or brain-sensing headphones.

High-bandwidth BCI is the least mature commercial category. The intended customer model is becoming clearer, but companies including Neuralink, Synchron and Paradromics are still funded mainly by investors while their permanent interfaces remain in clinical trials.

Finally, software, neural-data products and licensing deals are emerging around all of these businesses. For now, they show up more often as extra monetization layers than as large standalone neurotech businesses.

Neurotech business model	Who pays?	How the company gets paid	Commercial maturity today
Therapeutic implants	Insurers, public healthcare, hospitals	Implant, procedure-related products, replacements	Very proven
Clinical monitoring	Hospitals	Disposable sensors, subscriptions, equipment	Proven and growing
Research tools	Universities, labs, companies	Hardware, software licences, support	Established niche
Consumer neurotech	Consumers	Device purchase, optional subscription	Proven at modest scale
High-bandwidth BCI	Eventually hospitals and healthcare payers	Implant, procedure, support, software	Mostly clinical-stage
Data, software and licensing	Hospitals, researchers, technology partners	SaaS, licences, integrations	Growing secondary layer

Why are implanted neurostimulators making so much more money than BCIs?

Implanted neurostimulation is already a multibillion-dollar neurotech business because companies have solved the entire route from clinical evidence to physician adoption and reimbursement.

Medtronic gives us the clearest scale reference. Its neuromodulation sales went from $1.75 billion in fiscal 2024 to $1.93 billion in 2025 and $2.07 billion in 2026. That works out to roughly 18% growth in two years from an already very large base. Its latest annual report says growth was helped by products such as the Inceptiv closed-loop spinal-cord stimulator and Percept RC system with BrainSense technology.

LivaNova shows that this is broader than one diversified medical-device giant. Its latest quarterly results put neuromodulation revenue at $166.9 million, 10% above the previous year, with growth in every major region. NeuroPace is starting from a much smaller base, yet its core RNS revenue grew 21% in its latest quarter and management still expects roughly 21% to 23% underlying RNS growth for the year.

At three very different scales, the pattern is the same. Once a neurostimulation product works well enough, physicians know how to use it, hospitals can afford the procedure and reimbursement exists, the company can keep adding patients for years.

BCI companies have solved only part of that equation so far. Neuralink can show people controlling computers with their thoughts, but a reimbursed commercial market requires far more: regulatory approval, reliable surgery, manufacturing at scale, trained clinical centers, long-term support and a payer willing to cover the cost.

That gap explains why apparently less futuristic neurotech is making far more money today.

If you want more recent data on this point, please see our latest neurotechnology market report.

How does a neurotech company keep making money after the first device sale?

Recurring neurotech revenue often comes from replacement implants and single-use sensors before it comes from software.

LivaNova’s VNS Therapy is a good example. A patient receives an implanted pulse generator connected to a lead. When the generator eventually reaches the end of its service life, physicians can replace the generator while leaving the lead in place. The company gets another sale from an existing patient years after the original procedure.

Clinical monitoring can create recurrence much faster. Ceribell places its rapid-response EEG technology inside hospitals, but every additional patient requires a disposable wearable headband. In its latest quarter, $21.2 million of Ceribell’s $28.1 million revenue came from products, while $6.9 million came from subscriptions.

Roughly three-quarters of Ceribell’s latest revenue still came from physical products even though the company has a genuine SaaS layer. The recurring business works because patient usage consumes another piece of hardware.

The best installed bases can therefore generate several forms of repeat spending. More patients create more disposables. Existing implant patients eventually need replacements. Hospitals can pay subscriptions. New software can be sold into an already established workflow.

The original hardware placement can be worth much more than the first invoice suggests.

Can hospital neurotech really make recurring SaaS-like revenue?

Yes. Hospital neurotech can produce real subscription revenue, and Ceribell gives us one of the clearest public examples, although physical consumables still drive most of its sales.

Ceribell sells a rapid-response EEG system used when clinicians need to detect seizures and other neurological abnormalities quickly. Instead of asking hospitals to buy a traditional EEG machine and stop there, Ceribell combines disposable patient headbands with monthly access to its Clarity software, EEG recorders and online portal.

The model is gaining traction. Ceribell’s revenue rose from $65.4 million in 2024 to $89.1 million in 2025. In its latest quarter, revenue reached $28.1 million, 33% higher than a year earlier, while the number of active accounts reached 712.

The recurring part is also becoming meaningful. Ceribell reported $21.7 million of subscription revenue in 2025, around 24% of total sales, and disclosed a 97% gross margin on that subscription revenue. Its latest quarter produced another $6.9 million of subscriptions.

The attractive part is the connection between software and actual clinical activity. Ceribell does not have to persuade hospitals to buy an abstract analytics dashboard. The software helps clinicians interpret EEG recordings produced by the same system, while higher patient usage creates more disposable-headband sales.

That gives the company two ways to grow inside the same hospital: add the recurring subscription and increase the number of patients using the system.

Ceribell metric	2024	2025	Latest quarter
Revenue	$65.4M	$89.1M	$28.1M
Growth	45%	36%	33% YoY
Subscription revenue	$15.4M	$21.7M	$6.9M
Active accounts	500+ around year-end	647	712

Does reimbursement decide whether a medical neurotech product actually sells?

For medical neurotechnology, reimbursement can decide whether a good product becomes a real business.

LivaNova recently provided an unusually clean example. Medicare changed reimbursement for its VNS Therapy procedures in the US, increasing hospital outpatient payments by approximately 48% for new patient implants and 47% for end-of-service procedures compared with the previous rates.

The technology itself did not suddenly become 48% better. What changed was the hospital’s financial reason to offer it.

LivaNova had specifically described reimbursement as a barrier because the old payment could fail to cover the hospital’s procedure costs. The new rates make it much easier for a hospital to perform the procedure without losing money. Its latest results are already showing continued implant growth, although it is too early to pin that growth entirely on reimbursement.

The dollar amounts involved show why payment pathways matter so much. NeuroPace’s latest annual filing estimates an average Medicare hospital payment of around $45,000 for a VNS implantation in 2026. For its own RNS procedure, NeuroPace says the relevant hospital payments depend on the procedure and coding, while physician reimbursement alone can run above $3,000.

Ceribell is approaching the same problem from the diagnostic side. The company has secured a Medicare New Technology Add-on Payment for its delirium-monitoring solution that takes effect later this year, giving hospitals another financial reason to adopt the technology.

This is one of the biggest differences between medical and consumer neurotech. A consumer headset needs someone to pull out a credit card. A clinical neurotech product can become part of an existing healthcare payment system worth tens of thousands of dollars per procedure.

If you want more recent data on this point, please see our latest neurotechnology market report.

If neurotech gross margins are so high, why do these companies still lose money?

High neurotech gross margins are real, but sales teams, clinical evidence, regulatory work and product development can swallow almost all of that gross profit.

NeuroPace generated $22.8 million of revenue in its latest quarter with an 82.8% GAAP gross margin. That means it produced about $18.9 million of gross profit. Yet operating expenses were $24 million, leaving a GAAP net loss of $6.2 million.

The cost structure explains the gap. NeuroPace spent more than $12 million on sales and marketing in the quarter and another $6.9 million on R&D. A brain implant does not sell itself because its manufacturing cost is low. The company needs neurosurgeons, epilepsy centers, clinical evidence, patient identification, training, regulatory work and years of product development around the implant.

The same broader pattern shows up elsewhere. Ceribell reported an 88% gross margin for 2025 but still lost $53.4 million for the year because it was spending heavily to expand hospital adoption and develop new products. Axonics, before its acquisition, was already around a 75% gross margin while moving toward positive adjusted EBITDA. Nevro also had healthy device-level margins, yet falling sales and heavy operating costs eventually destroyed much of the value of the company.

So the familiar claim that neurotech can have “software-like margins” needs a big asterisk. It sometimes can at the gross-profit line. Building the clinical machine needed to produce those sales is much more expensive than shipping another software seat.

The economics get much more interesting when revenue starts growing faster than that clinical and commercial infrastructure.

Why was Axonics worth billions while Nevro sold for only $250 million?

Axonics was worth billions while Nevro sold for roughly $250 million because buyers rewarded fast growth, strong economics and a healthy clinical franchise; Nevro’s larger revenue base could not compensate for a deteriorating business.

Boston Scientific agreed to pay about $3.7 billion in equity value for Axonics. At the time, Axonics was expected to generate roughly $366 million of annual revenue, up about 34%, with gross margins around 75%. Boston Scientific also said Axonics had treated approximately 100,000 incontinence patients globally during 2023.

Nevro entered its Globus Medical deal from a very different position. The spinal-cord-stimulation company generated $408.5 million of revenue in 2024, meaning it was actually larger than Axonics had been when the Boston Scientific deal was announced. Revenue, however, had fallen about 4%, and Nevro had spent years struggling with growth and profitability.

Globus ultimately bought Nevro for approximately $250 million of equity value.

Using the headline equity values against the companies’ latest annual revenue at the time gives a rough ratio of about 10 times revenue for Axonics versus roughly 0.6 times for Nevro. These are deliberately simple ratios rather than formal enterprise-value multiples, but a gap of this size is still hard to ignore.

Neurotechnology revenue therefore carries wildly different value depending on whether doctors are adopting the product faster, the market is still underpenetrated and the company can turn its installed base into profitable growth.

Company at transaction	Annual revenue around deal	Revenue trend	Headline equity value
Axonics	≈$366M	≈+34%	≈$3.7B
Nevro	$408.5M	≈-4%	≈$250M
Rough equity value / revenue	≈10x	—	≈0.6x

If you want more recent data on this point, please see our latest neurotechnology market report.

How are Neuralink, Synchron, Precision and Paradromics supposed to make money?

Neuralink, Synchron, Precision and Paradromics are aiming for reimbursed implant-and-service businesses, even though investor capital still pays most of the bills today.

The financing numbers make the current stage obvious. Neuralink raised $650 million in its Series E. Synchron followed with a $200 million Series D, bringing its total funding to roughly $345 million. Together, those two rounds alone injected $850 million into companies that have yet to build large commercial implant businesses.

Clinical scale remains small by medical-device standards. Neuralink reported 21 participants across its trials earlier this year, although that was already a sharp jump from only three participants a year earlier. Paradromics recently implanted the first participant in its long-term Connect-One study. Synchron is pushing its Stentrode toward commercialization after years of clinical development.

The eventual revenue model is easier to imagine than the current financial statements. A healthcare system could pay for the implant and implantation procedure, while the company provides programming, clinical support, software and future hardware upgrades. Additional indications could let the same technical platform address communication, computer control, movement, vision or other neurological problems.

That last part is where the huge valuations become understandable. A successful BCI company would prefer to avoid building a single-product business around one disability. Neuralink already has active work around computer control and communication, with vision restoration listed as an upcoming clinical program. Paradromics describes speech restoration as the first application of a broader platform.

Still, the future model and the current one are very different. Today these companies are mainly converting venture capital into clinical evidence. The real business begins when hospitals and healthcare payers start funding repeatable procedures.

Can BCI companies make money before permanent brain implants are approved?

BCI companies can earn earlier revenue by selling temporary clinical interfaces and research systems while permanent implants stay in trials.

Precision Neuroscience is moving furthest down this path. Its Layer 7 Cortical Interface already has FDA 510(k) clearance for recording, monitoring and stimulating electrical activity on the brain surface for up to 30 days. Precision says the interface has now been used in more than 95 patients and that it works with more than 15 hospital partners.

That creates a much nearer-term medical product around areas such as intraoperative brain mapping and neurological monitoring. Precision can build hospital relationships, manufacturing experience and clinical evidence while continuing to develop the longer-term BCI opportunity. Its partnership with Medtronic is especially interesting because Layer 7 is being integrated with Medtronic’s neurosurgical technology rather than waiting for Precision to build an entire operating-room ecosystem alone.

Blackrock Neurotech shows another route. The company has been selling neurophysiology research equipment for years while pursuing more advanced BCI systems. Blackrock says its research products are used in more than 1,000 laboratories across 53 countries, and its NeuroPort neural-signal system has become a widely used platform for human BCI research.

The market is smaller than the eventual market these companies hope to reach with permanent BCIs, but it gives them something most implant startups lack: customers before the final product is ready.

This will likely remain an important model in neurotech. A company that can commercialize useful pieces of its technology during the long regulatory journey is in a better position than one that has to finance ten years of development before earning its first meaningful dollar.

Can neurotech companies make money from brain data and software alone?

Brain data and neurotech software can make money, but as of now they work best as paid layers attached to hardware or clinical workflows.

NeuroPace has one of the strongest neural datasets in commercial neurotechnology. Its RNS implants continuously collect intracranial EEG information from people with epilepsy over long periods, producing data that conventional short hospital EEG sessions cannot easily reproduce. The company is now building AI-enabled tools such as ECoG Assistant around that data.

Yet customers still mainly pay NeuroPace for the RNS system. The data makes the system better, helps physicians interpret recordings and may increase the advantage NeuroPace has accumulated over competitors.

Emotiv gives us a more explicit software model on the research side. Its EPOC X EEG headset currently costs $1,199, while its EmotivPRO Standard research software costs $89 per month when billed annually, or $1,068 per year. A customer keeping that software for several years can therefore spend as much on software as on the original headset.

Licensing also lets neurotech companies reach customers without owning every part of the final product. Precision’s work with Medtronic puts Precision’s neural interface inside a much larger neurosurgical ecosystem. Consumer companies such as Neurable have put EEG sensing into ordinary-looking premium headphones rather than forcing the user to buy a separate laboratory-style headset.

For now, neural data becomes commercially powerful when it improves a device, supports a paid software tool or makes another company’s product smarter. There is still very little evidence of large neurotech companies making most of their money simply by selling datasets.

If you want more recent data on this point, please see our latest neurotechnology market report.

Can consumer neurotech become more than a one-off gadget business?

Consumer neurotech is still mostly a premium-device business, with subscriptions adding revenue rather than carrying the economics.

The current pricing makes that clear. Neurable sells its MW75 Neuro LT EEG headphones for $499. The product turns brain signals into features around focus, cognitive strain, mental recovery and brain-health tracking. Muse currently advertises one of its EEG headsets at about $250, while its Premium service costs around $50 per year.

At those prices, a single Muse hardware purchase equals roughly five years of Premium subscription revenue before we even consider discounts, customer churn or the higher margin software may carry. Neurable’s $499 hardware price similarly gives it a meaningful amount of revenue up front.

This is quite different from something like WHOOP or many software-first health platforms, where recurring membership can dominate lifetime customer value. Neurotech consumers are still paying primarily for access to a physical sensor that can measure something other wearables cannot.

There is a plausible route toward better recurring economics. Brain-health tracking could become useful enough that people keep paying for interpretation, coaching, longitudinal comparisons and new algorithms after buying the device. Hardware could also disappear into products people already use every day, particularly headphones and earbuds.

That model has not been proven at mass-market scale yet. Consumer neurotech currently looks much closer to premium wearables with a software layer than to a pure subscription business.

So which neurotechnology business models actually work best today?

The strongest neurotechnology business model today is reimbursed clinical hardware with repeat usage, replacements or consumables; high-bandwidth BCI offers much bigger theoretical upside but has far less commercial proof.

If we rank models by demonstrated economics rather than excitement, therapeutic neuromodulation comes first. Medtronic is already above $2 billion a year in neuromodulation, LivaNova continues to grow its VNS implant business and NeuroPace is producing more than 20% underlying growth in its responsive brain-stimulation franchise. These companies get paid for solving severe medical problems inside established clinical pathways.

Clinical monitoring may have even cleaner recurring economics when the product is used frequently. Ceribell has managed to combine hospital subscriptions with single-use EEG wearables, creating revenue every time another patient is monitored. That model can compound through both new hospital accounts and higher usage inside existing accounts.

Research tools are a smaller but very real business. Blackrock Neurotech’s presence in more than 1,000 labs and Emotiv’s hardware-plus-software pricing show that universities and companies will pay for access to useful neural signals without waiting for a mass consumer BCI market.

Consumer neurotech works too, although the economics remain heavily dependent on hardware purchases. Subscriptions are starting to matter, but there is not convincing evidence yet that recurring consumer software has become the main revenue engine of the category.

BCI sits at the opposite extreme. Neuralink, Synchron, Precision and Paradromics could eventually combine implants, procedures, software, upgrades and multiple neurological applications into much larger businesses. Right now, however, financing and clinical milestones tell us far more about those companies than revenue does.

The broader lesson is fairly practical. The neurotech companies making serious money are usually the ones that solve one expensive neurological problem, fit into an existing clinical workflow, get reimbursement right and then find ways to earn again from the installed patient or hospital. Proprietary brain data, AI and software can make that relationship much stronger, but they usually come after the basic medical business works.

That leaves a clear hierarchy. Reimbursed implants and recurring clinical monitoring are already proven business models. Research tools and consumer hardware are real but smaller. Software and licensing are useful additional layers. General-purpose BCI platforms remain the biggest potential prize and, commercially, the least proven part of neurotechnology.

If you want more recent data on this point, please see our latest neurotechnology market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.